【作者】 孙海滨；

【导师】 刘俊峰；

【作者基本信息】 河北医科大学 ， 外科学， 2010， 硕士

【摘要】 近10年来,国内外有大量关于食管癌新辅助治疗的研究,大多数肯定了食管癌新辅助治疗的疗效,认为局部晚期食管癌进行新辅助治疗,能够使食管癌病人的肿瘤降期,提高食管癌患者的远期生存率。因此在国外食管癌的新辅助治疗广泛应用于临床,并已经成为西方国家治疗局部晚期食管癌的标准方案。未来食管癌新辅助治疗应加强食管癌分子生物学特性方面的研究,选择新型生物化疗药物制剂,提高对放化疗敏感性的分子水平预测,筛选出更合适的患者,进一步提高新辅助治疗的疗效。更多还原

【Abstract】 In the past decade, we have seen an increasing number of reports on the long-term curative effect and safety of preoperative chemotherapy and radiotherapy (neoadjuvant CRT) in treating advanced esophageal carcinoma. Neoadjuvant radiochemotherapy will both downstage the tumor and improve survival, which led to the widespread adoption of the therapy. CRT with or without surgery is the most common treatment strategy for resectable esophageal cancer in Western countries. To improve the curative effect of CRT, future investigation must focus on the development of new biologic or chemotherapeutic agents, and the identification of biologic markers that might predict response to chemoradiotherapy.更多还原